The present study was undertaken to assess the ability of ovarian hormones to alter methamphetamine (MA)-induced dopaminergic toxicity in male and female mice gonadectomized at 4 and 6 weeks of age. None of the following three treatments, estradiol benzoate (EB, 3 × 0.47 µg), progesterone (Prog, 3 × 0.47 µg), or EB (2 × 0.47 µg) followed by Prog (0.47 µg), affected the dopamine (DA)-depleting effects of MA in male and female mice gonadectomized when they were 4 weeks old. However, in contrast to the findings that male mice are more sensitive to MA-induced DA depletion than female mice, no sexual differences in the sensitivity to MA treatment were observed in mice gonadectomized at this age. Moreover, three daily doses of EB (0.47 µg) and EB (0.47 µg) combined with 4-hydroxytamoxifen (4OHT, 6 µg) effectively attenuated striatal DA depletion produced by MA in female mice ovariectomized at 6 weeks of age. Three daily doses of Prog (0.47 µg) and EB (0.47 µg) combined with 4OHT (6 µg) significantly attenuated MA-induced striatal DA depletion in male mice gonadectomized at 6 weeks of age. Taken together, the modulating effects of ovarian hormones on MA-induced DA depletion in mouse striatum could be sex- and age-dependent. 4OHT did not block the protecting effects of EB on MA-induced DA depletion in female and male mice, suggesting that the estrogen receptor may not be involved in the protective effects of EB on attenuating MA-induced DA toxicity.

Keywords:
Methamphetamines, Gonadal steroids, Gonadal steroid antagonists, Catecholamines, Neurotoxicity, Gonadectomy
1.
Wagner GC, Seiden LS, Schuster CR: Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs. Drug Alcohol Depend 1979;4:435–438.
2.
Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller JM, Westly J: Long-lasting depletion of striatal dopamine and loss of dopamine uptake sites following the repeated administration of methamphetamine. Brain Res 1980;171:151–160.
3.
Wagner GC, Tekirian TL, Cheo CT: Sexual differences in sensitivity to methamphetamine toxicity. J Neural Transm 1993;93:67–70.
4.
Yu L, Liao P-C: Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J Neural Transm 2000;107:419–427.
5.
Yu L, Liao P-C: Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice. J Neural Transm 2000;107:1139–1147.
6.
Hruska RE, Silbergeld EK: Increased dopamine receptor sensitivity after estrogen treatment using the rat rotation model. Science 1980;208:1466–1468.
7.
Dluzen DE, McDermott JL, Liu B: Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996;18:603–606.
8.
Callier S, Morissette M, Grandbois M, Di Paolo T: Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. Synapse 2000;37:245–251.
9.
Gao X, Dluzen DE: The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Brain Res 2001;892:63–69.
10.
Gao X, Dluzen DE: Tamoxifen abolishes estrogen’s neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 2001;103:385–394.
11.
Dluzen DE, McDermott JL, Anderson LI: Tamoxifen eliminates estrogen’s neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system. Neurotoxicity Res 2001;3:291–300.
12.
MacGregor SJ, Liu H, Bentrem DJ, Zapf JW, Jordan VC: Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 2000;60:5097–5105.
13.
Miller DB, Ali SF, O’Callaghan JP, Laws SC: The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann NY Acad Sci 1998;844:153–165.
14.
Dluzen DE: Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res 1997;767:340–344.
15.
Dluzen DE, McDermott JL, Liu B: Estrogen alters MPTP-induced neurotoxicity in female mice: Effects on striatal dopamine concentrations and release. J Neurochem 1996;66:658–666.
16.
Peris J, Decambre N, Coleman-Hardee ML, Simpkins JW: Estradiol enhances behavioral sensitization to cocaine and amphetamine-stimulated striatal [3H]dopamine release. Brain Res 1991;566:255–264.
17.
Becker JB: Estrogen rapidly potentiates amphetamine-induced striatal dopamine release and rotational behavior during microdialysis. Neurosci Lett 1990;118:169–171.
18.
Becker JB, Beer ME, Robinson TE: Striatal dopamine release stimulated by amphetamine or potassium: Influence of ovarian hormones and the light-dark cycle. Brain Res 1984;311:157–160.
19.
Agarwal VR, Sinton CM, Liang C, Fisher C, German DC, Simpson ER: Upregulation of estrogen receptors in the forebrain of aromatases knockout (ArKO) mice. Mol Cell Endocrinol 2000;162:9–16.
20.
Lammers CH, D’Souza U, Qin ZH, Lee SH, Yajima S, Mouradian MM: Regulation of striatal dopamine receptors by estrogen. Synapse 1999;34:222–227.
21.
McDermott JL, Anderson LI, Dluzen DE: Tamoxifen alters dopamine release through direct actions upon superfused corpus striatal tissue fragments. Neurochem Int 1998;32:299–307.
22.
McDermott JL, Anderson LI, Dluzen DE: Interactive effects of tamoxifen and estrogen upon the nigrostriatal dopaminergic system. Neuroendocrinology 1997;66:181–187.
23.
Wiseman H: Tamoxifen: New membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol Sci 1994;15:83–89.
24.
Weisz J, Gunsalus P: Estrogen levels in immature female rats: True or spurious-ovarian or adrenal? Endocrinology 1973;93:1057–1063.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.